|
| Study | Publish year country
(study Yrs) | Increased risk (OR with 95% CI) | Cancer type(s) |
|
| Evans et al. [79] case-control hospitalized patients | 2005 Scotland
(1993–2001) | No
(i) Metformin (OR 0.77) | | None specified (All incidence of cancers) |
|
| Bowker et al. [80] retrospective | 2006 Canada
(1991–1996) | | Yes
(i) SFU compared to metformin (HR 1.3, )
(ii) Insulin (HR 1.9, ) | None specified (Looked specifically at cancer-related mortality and not cancer type.) |
|
| Monami et al. [81] case control | 2009 Italy
(1998–2004) | After >36 months of use:
No
(i) Acarbose (OR 0.77)
(ii) Glicazide (OR 0.40)
(iii) Glitazones (OR 1.05)
(iv) Insulin (OR 0.91)
(v) Metformin (OR 0.28)
(vi) Other SFU (OR 1.05)
(vii) Repaglinide (OR 0.87) | After >36 months of use:
Yes
(i) Glibenclamide (OR 2.62, ) | GI breast
genital tract
(male/female)
pancreas
lung |
|
| Li et al. [64] case control hospitalized patients | 2009 United States
(2004–2008) | No
(i) Metformin (OR 0.38) | Yes
(i) Insulin (OR 4.99)
(ii) Insulin secretagogues (OR 2.52)
(iii) TZD’s (OR 1.55) | Pancreas (adenocarcinoma) |
|
| Mannucci et al. [82] case control | 2010 Italy
(1998–2007) | No
(i) Other insulin: lispro, aspart, and human insulin
(ii) Metformin | Yes
(i) ≥0.3 IU/kg/d of glargine | GI
hepatic
pancreatic
lung
leukemia/lymphoma
breast
urogenital
prostate
20 “other cancers” |
|
